Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Octapharma’s balanced portfolio built on a very special juice

Octapharma’s balanced portfolio built on a very special juice AbstractOctapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Journal of Haemophilia Practice de Gruyter

Octapharma’s balanced portfolio built on a very special juice

The Journal of Haemophilia Practice , Volume 1 (2): 3 – May 1, 2013

Loading next page...
 
/lp/de-gruyter/octapharma-s-balanced-portfolio-built-on-a-very-special-juice-GU1cuiEGHW

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
de Gruyter
Copyright
© 2014 Kate Khair, published by Sciendo
eISSN
2055-3390
DOI
10.17225/jhp.00023
Publisher site
See Article on Publisher Site

Abstract

AbstractOctapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair

Journal

The Journal of Haemophilia Practicede Gruyter

Published: May 1, 2013

There are no references for this article.